212 related articles for article (PubMed ID: 9680099)
21. The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines with varying lipophilicity.
Mülder HS; Dekker H; Pinedo HM; Lankelma J
Biochem Pharmacol; 1995 Sep; 50(7):967-74. PubMed ID: 7575681
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the kinetics of active efflux of 99mTc-MIBI in cells with P-glycoprotein-mediated and multidrug-resistance protein-associated multidrug-resistance phenotypes.
Vergote J; Moretti JL; de Vries EG; Garnier-Suillerot A
Eur J Biochem; 1998 Feb; 252(1):140-6. PubMed ID: 9523723
[TBL] [Abstract][Full Text] [Related]
23. Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines.
Roovers DJ; van Vliet M; Bloem AC; Lokhorst HM
Leuk Res; 1999 Jun; 23(6):539-48. PubMed ID: 10374847
[TBL] [Abstract][Full Text] [Related]
24. Reversal of multidrug resistance in breast cancer cells by a combination of ursolic acid with doxorubicin.
Zong L; Cheng G; Liu S; Pi Z; Liu Z; Song F
J Pharm Biomed Anal; 2019 Feb; 165():268-275. PubMed ID: 30572191
[TBL] [Abstract][Full Text] [Related]
25. Kinetics of anthracycline efflux from multidrug resistance protein-expressing cancer cells compared with P-glycoprotein-expressing cancer cells.
Marbeuf-Gueye C; Broxterman HJ; Dubru F; Priebe W; Garnier-Suillerot A
Mol Pharmacol; 1998 Jan; 53(1):141-7. PubMed ID: 9443942
[TBL] [Abstract][Full Text] [Related]
26. Isolation and characterization of daunorubicin-resistant AML-2 sublines.
Choi CH; Ling V
Mol Cells; 1997 Apr; 7(2):170-7. PubMed ID: 9163728
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and biological activities of a 3'-azido analogue of Doxorubicin against drug-resistant cancer cells.
Yu S; Zhang G; Zhang W; Luo H; Qiu L; Liu Q; Sun D; Wang PG; Wang F
Int J Mol Sci; 2012; 13(3):3671-3684. PubMed ID: 22489175
[TBL] [Abstract][Full Text] [Related]
28. Monensin and verapamil do not alter intracellular localisation of daunorubicin in multidrug resistant human KB cells.
Wood DJ; Rumsby MG; Warr JR
Cancer Lett; 1996 Nov; 108(1):41-7. PubMed ID: 8950207
[TBL] [Abstract][Full Text] [Related]
29. Retention of activity by selected anthracyclines in a multidrug resistant human large cell lung carcinoma line without P-glycoprotein hyperexpression.
Coley HM; Workman P; Twentyman PR
Br J Cancer; 1991 Mar; 63(3):351-7. PubMed ID: 1672252
[TBL] [Abstract][Full Text] [Related]
30. Lack of competition of substrates for P-glycoprotein in MCF-7 breast cancer cells overexpressing MDR1.
Hall JG; Cory AH; Cory JG
Adv Enzyme Regul; 1999; 39():113-28. PubMed ID: 10470369
[TBL] [Abstract][Full Text] [Related]
31. Increase in doxorubicin cytotoxicity by inhibition of P-glycoprotein activity with lomerizine.
Shiraki N; Hamada A; Ohmura T; Tokunaga J; Oyama N; Nakano M
Biol Pharm Bull; 2001 May; 24(5):555-7. PubMed ID: 11379779
[TBL] [Abstract][Full Text] [Related]
32. Transport mechanisms of anthracycline derivatives in human leukemia cell lines: uptake of pirarubicin, daunorubicin and doxorubicin by K562 and multidrug-resistant K562/ADM cells.
Nagasawa K; Takara K; Nomiyama M; Ohnishi N; Yokoyama T
Biol Pharm Bull; 1996 Jul; 19(7):971-6. PubMed ID: 8839972
[TBL] [Abstract][Full Text] [Related]
33. Enhancement of doxorubicin activity in multidrug-resistant cells by mefloquine.
Fujita R; Ishikawa M; Takayanagi M; Takayanagi Y; Sasaki K
Methods Find Exp Clin Pharmacol; 2000 Jun; 22(5):281-4. PubMed ID: 11031728
[TBL] [Abstract][Full Text] [Related]
34. Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity.
Jonsson O; Behnam-Motlagh P; Persson M; Henriksson R; Grankvist K
Biochem Pharmacol; 1999 Dec; 58(11):1801-6. PubMed ID: 10571255
[TBL] [Abstract][Full Text] [Related]
35. Differential expression and activity of P-glycoprotein and multidrug resistance-associated protein in CD34-positive KG1a leukemic cells.
Fardel O; Payen L; Courtois A; Drenou B; Fauchet R; Rault B
Int J Oncol; 1998 Feb; 12(2):315-9. PubMed ID: 9458355
[TBL] [Abstract][Full Text] [Related]
36. Vesicular anthracycline accumulation in doxorubicin-selected U-937 cells: participation of lysosomes.
Hurwitz SJ; Terashima M; Mizunuma N; Slapak CA
Blood; 1997 May; 89(10):3745-54. PubMed ID: 9160680
[TBL] [Abstract][Full Text] [Related]
37. Cellular pharmacology of lipophilic anthracyclines in human tumor cells in culture selected for resistance to doxorubicin.
Bennis S; Faure P; Chapey C; Hu YP; Fourche J; El Yamani J; Robert J
Anticancer Drugs; 1997 Jul; 8(6):610-7. PubMed ID: 9300576
[TBL] [Abstract][Full Text] [Related]
38. Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative.
Dale IL; Tuffley W; Callaghan R; Holmes JA; Martin K; Luscombe M; Mistry P; Ryder H; Stewart AJ; Charlton P; Twentyman PR; Bevan P
Br J Cancer; 1998 Oct; 78(7):885-92. PubMed ID: 9764579
[TBL] [Abstract][Full Text] [Related]
39. Effect of Calphostin C (PKC inhibitor) on daunorubicin resistance in P388/ADR and HL60/AR cells: reversal of drug resistance possibly via P-glycoprotein.
Gupta S; Patel K; Singh H; Gollapudi S
Cancer Lett; 1994 Jan; 76(2-3):139-45. PubMed ID: 7511983
[TBL] [Abstract][Full Text] [Related]
40. Modification by brefeldin A, bafilomycin A1 and 7-chloro-4-nitrobenz-2-oxa-1,3-diazole (NBD) of cellular accumulation and intracellular distribution of anthracyclines in the non-P-glycoprotein-mediated multidrug-resistant cell line COR-L23/R.
Rhodes T; Barrand MA; Twentyman PR
Br J Cancer; 1994 Jul; 70(1):60-6. PubMed ID: 7912544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
